Heron Therapeutics, INC /DE/ 10-Q quarterly reports

Heron Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing a net loss of $5.5 million, a decline in oncology sales, and ongoing efforts to regain Nasdaq's minimum bid price compliance.

Heron Therapeutics reported a net loss of $8.1 million for Q1 2026, with net product sales decreasing to $34.7 million compared to $38.9 million in the prior year period.

Heron Therapeutics reports strong acute care product sales growth and a significant debt refinancing, despite a one-time loss on debt extinguishment.

Heron Therapeutics reported a net income for the first half of 2025, driven by strong acute care product sales and reduced operating expenses, while successfully refinancing its debt.

Heron Therapeutics achieves profitability in Q1 2025, driven by strong growth in its acute care product portfolio and strategic cost management.

Heron Therapeutics saw a revenue increase in Q3 2024 compared to Q3 2023, while also reducing its net loss.

Heron Therapeutics saw a rise in product sales during the second quarter of 2024, but still experienced a net loss.

Heron Therapeutics saw a revenue increase and a significant reduction in net losses in the first quarter of 2024 compared to the same period last year.